PharmNXT Brings European Bioprocess Engineering to India with Strategic DTR Acquisition
28th July 2025: In a landmark development for India’s biopharmaceutical sector, PharmNXT Biotech has acquired Defined Tubing Routing (DTR), a globally recognised player from Ireland, working in advanced bioprocess tubing solutions. This move enables PharmNXT to access technology solutions related to single-use systems, strengthening its capacity to serve pharmaceutical and biopharma clients with more tailored and technically aligned offerings.
With the addition of DTR’s modular tubing systems, capable of supporting bioprocess volumes from 20 L to 500 L and custom spans up to 2.9 meters, PharmNXT significantly expands its engineering capabilities, faster turnaround, enhanced customisation, and stronger compliance. DTR systems are increasingly being adopted in biopharmaceutical manufacturing, especially within single-use technology setups where efficient tubing management is critical. These systems help reduce operational risks by minimizing trip hazards and clearly outlining flow paths, thereby supporting safety and compliance.
“This is a defining moment for the Indian biopharmaceutical sector,” said Sachin Joshi, Founder and Managing Director at PharmNXT. “With this acquisition, PharmNXT will introduce an innovative range of new solutions for biopharmaceutical and pharmaceutical customers worldwide. DTR is an innovative solution to address issues related to single-use tubing management. DTR systems are designed to handle single-use tubing in pharmaceutical and biotech/biopharma facilities, ensuring proper routing, reducing errors, and enhancing the overall appearance of the facility.
Ankush Kapoor, Founder and CEO of PharmNXT Biotech, says, “We are really excited about this acquisition, which is highly strategic and complements our manufacturing capabilities in single-use technologies-consumables and process equipment. The addition of DTR systems allows customers to access the full range of solutions in single-use technologies from PharmNXT. David Walton, the former owner of DTR, brings invaluable industry knowledge, further strengthening our technical leadership. David’s extensive experience, expertise, and global customer base in this space will play a pivotal role in accelerating the growth of PharmNXT’s end-to-end single-use solutions portfolio in the US, Europe, and Asia.”
Former DTR owner, Mr Walton, is going to be a strategic advisor to PharmNXT’s leadership team, offering continuity and strategic direction. He added, “I’m excited to be associated with PharmNXT team. Our combined strengths open up new possibilities in R&D and product customization, especially for clients operating in tightly regulated markets. I look forward to contributing to PharmNXT’s mission of delivering high-quality, scalable solutions to customers worldwide.”
India‘s pharmaceutical exports crossed $30 billion in the FY25, driven by low-cost innovation, technical skill, and regulatory adaptability. PharmNXT’s acquisition comes at a time when global pharma companies are looking for robust, de-risked supply chains, making India not just a backup but a preferred partner in biotech infrastructure.